Repligen
RGEN
#1859
Rank
NZ$19.86 B
Marketcap
NZ$310.72
Share price
2.97%
Change (1 day)
20.03%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of June 2026 : NZ$1.23 Billion

According to Repligen 's latest financial reports the company's total debt is NZ$1.23 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2026)

Total debt by year

Year Total debt Change
2025-12-31NZ$1.19 B-2.1%
2024-12-31NZ$1.21 B8.11%
2023-12-31NZ$1.12 B68.96%
2022-12-31NZ$0.66 B24.31%
2021-12-31NZ$0.53 B40.4%
2020-12-31NZ$0.38 B-2.37%
2019-12-31NZ$0.39 B153.42%
2018-12-31NZ$0.15 B10.4%
2017-12-31NZ$0.13 B1.61%
2016-12-31NZ$0.13 B
2005-03-31NZ$0.16 M31.36%
2004-03-31NZ$0.12 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
NZ$113.18 B 9,046.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
NZ$76.20 B 6,058.11%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
NZ$34.61 B 2,696.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$80.25 B 6,385.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
NZ$34.62 M-97.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
NZ$0.53 B-56.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
NZ$0.71 B-41.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
NZ$0.51 B-58.16%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
NZ$7.52 B 508.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
NZ$5.42 B 338.20%๐Ÿ‡บ๐Ÿ‡ธ USA